Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.39 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 3/20 | 0.36 |
| ▸ | FAP | Q12884 | 1/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.35 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | CCR3 | P51677 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3258336 | 1.00 | MAOB (0.39) | MAOBADAM17GRM2MAOAHTR1A | |
| SCHEMBL3133531 | 0.88 | DPP4 (0.38) | MAOBADAM17MAOADPP4DPP8 | |
| SCHEMBL7368940 | 0.85 | CCR3 (0.38) | MAOBHTR1AHTR7DPP4FAP | |
| SCHEMBL3145715 | 0.85 | MAOB (0.37) | MAOBGRM2HTR1AHTR7DPP4 | |
| SCHEMBL3136103 | 0.84 | HTR1A (0.50) | MAOBGRM2MAOAHTR1AHTR7 | |
| SCHEMBL6052882 | 0.82 | SCN3A (0.41) | MAOBADAM17HTR1AHTR7DPP4 | |
| SCHEMBL7371918 | 0.81 | ADAM17 (0.49) | MAOBADAM17MAOA | |
| SCHEMBL3137156 | 0.81 | GBA1 (0.37) | MAOBHTR1AHTR7DPP4FAP | |
| SCHEMBL3129734 | 0.81 | GBA1 (0.37) | MAOBHTR1AHTR7DPP4FAP | |
| SCHEMBL6164036 | 0.80 | MMP1 (0.42) | MAOBADAM17MAOAHTR1AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298745-A1 | Treatment of Diabetes with Glycogen Phosphorylase Inhibitors | PROSIDION LIMITED (GB) | 2009-12-03 | — | — | US | claimed |
| WO-2006059163-A1 | TREATMENT OF DIABETES WITH GLYCOGEN PHOSPHORYLASE INHIBITORS | PROSIDION LIMITED (GB) | 2006-06-08 | — | — | WO | claimed |
| US-20050171049-A1 | Compounds for the treatment of ischemia | DENINNO MICHAEL P (US) | 2005-08-04 | — | — | US | claimed |
| EP-1056729-B1 | N-[(SUBSTITUTED FIVE-MEMBERED DI- OR TRIAZA DIUNSATURATED RING)CARBONYL]GUANIDINE DERIVATIVES FOR THE TREATMENT OF ISCHEMIA | PFIZER PROD INC (US) | 2004-12-29 | — | — | EP | claimed |
| US-20040198693-A1 | Compounds for the treatment of ischemia | DENINNO MICHAEL P (US) | 2004-10-07 | — | — | US | claimed |
| EP-1032424-B9 | COMBINATION OF AN ALDOSE REDUCTASE INHIBITOR AND A GLYCOGEN PHOSPHORYLASE INHIBITOR | PFIZER PROD INC (US) | 2004-10-06 | — | — | EP | claimed |
| EP-1454902-A1 | N- (substituted five-membered di-or triaza diunsaturated ring)carbonyl guanidine derivateives for the treatment of ischemia | Pfizer Products Inc. (US) | 2004-09-08 | — | — | EP | claimed |
| US-20040082614-A1 | Methods of treating infection using anitbiotics and glycogen phosphorylase inhibitors | PFIZER INC. | 2004-04-29 | — | — | US | claimed |
| WO-2004009084-A1 | METHODS OF TREATING INFECTION USING ANTIBIOTICS AND GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2004-01-29 | — | — | WO | claimed |
| US-20030149043-A1 | N-[(substituted five-membered di-or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia | PFIZER INC. | 2003-08-07 | — | — | US | claimed |
| EP-1149580-A1 | Use of heteroaryl substituted N-(Indole-2-Carbonyl-) amides for the manufacture of a medicament for the treatment of infection | Pfizer Products Inc. (US) | 2001-10-31 | — | — | EP | claimed |
| EP-0832065-B1 | SUBSTITUTED N-(INDOLE-2-CARBONYL)-GLYCINAMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER (US) | 2001-10-10 | — | — | EP | claimed |
| EP-1032424-B1 | COMBINATION OF AN ALDOSE REDUCTASE INHIBITOR AND A GLYCOGEN PHOSPHORYLASE INHIBITOR | PFIZER PROD INC (US) | 2001-09-12 | — | — | EP | claimed |
| EP-1061074-A1 | Novel process and intermediates | Pfizer Products Inc. (US) | 2000-12-20 | — | — | EP | claimed |
| EP-1056729-A1 | N-[(SUBSTITUTED FIVE-MEMBERED DI- OR TRIAZA DIUNSATURATED RING)CARBONYL]GUANIDINE DERIVATIVES FOR THE TREATMENT OF ISCHEMIA | Pfizer Products Inc. (US) | 2000-12-06 | — | — | EP | claimed |
| EP-1032424-A1 | COMBINATION OF AN ALDOSE REDUCTASE INHIBITOR AND A GLYCOGEN PHOSPHORYLASE INHIBITOR | Pfizer Products Inc. (US) | 2000-09-06 | — | — | EP | claimed |
| WO-1999043663-A1 | N-[(SUBSTITUTED FIVE-MEMBERED DI- OR TRIAZA DIUNSATURATED RING)CARBONYL] GUANIDINE DERIVATIVES FOR THE TREATMENT OF ISCHEMIA | PFIZER PRODUCTS INC. (US) | 1999-09-02 | — | — | WO | claimed |
| WO-1999026659-A1 | COMBINATION OF AN ALDOSE REDUCTASE INHIBITOR AND A GLYCOGEN PHOSPHORYLASE INHIBITOR | PFIZER PRODUCTS INC. (US) | 1999-06-03 | — | — | WO | claimed |
| EP-0832065-A1 | SUBSTITUTED N-(INDOLE-2-CARBONYL)-GLYCINAMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER INC. (US) | 1998-04-01 | — | — | EP | claimed |
| WO-1996039384-A1 | SUBSTITUTED N-(INDOLE-2-CARBONYL)-GLYCINAMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER, INC. (US) | 1996-12-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171049-A1 | Compounds for the treatment of ischemia | TNNI3, ADRB3, TBXA2R | MAOB 393/4885ADAM17 4400/4885GRM2 1579/4885 |
| US-20090298745-A1 | Treatment of Diabetes with Glycogen Phosphorylase Inhibitors | PYGL, PYGM, G6PC1 | MAOB 1909/4885ADAM17 1081/4885GRM2 3761/4885 |
| US-20040082614-A1 | Methods of treating infection using anitbiotics and glycogen phosphorylase inhibitors | PYGM, GYS1, MGAM | MAOB 2193/4885ADAM17 1038/4885GRM2 4305/4885 |
| US-20030149043-A1 | N-[(substituted five-membered di-or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia | NHERF1, SLC28A1, TNNI3 | MAOB 1411/4885ADAM17 2979/4885GRM2 1807/4885 |
| US-20040198693-A1 | Compounds for the treatment of ischemia | TNNI3, ADRB3, FABP3 | MAOB 778/4885ADAM17 4155/4885GRM2 1040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.